by Cary Miller | Jan 6, 2017 | Pharmaceutical, Trial Institution
By Unmesh Shah, Ph.D. and Cary Miller, Ph.D. The PTAB instituted an IPR on claims of Mayne Pharma International Pty Ltd.’s (“Mayne”) U.S. Patent No. 6,881,745 B2 covering formulations of azole antifungals in IPR2016-01186. In response to Merck Sharp & Dohme...
by Jones Day's PTAB Team | Jan 5, 2017 | Final Written Decisions, Pharmaceutical
By Raffaella Faraoni, Ph.D. and J. Patrick Elsevier, Ph.D. On December 22, 2016, in a final written decision in IPR2015-01537, the PTAB rejected an obviousness challenge brought by Momenta Pharmaceuticals, Inc. against a patent owned by Bristol-Myers Squibb directed...
by Jones Day's PTAB Team | Dec 26, 2016 | Pharmaceutical, Prior Art Issues
By Jeff Giering, Ph.D. and Cary Miller, Ph.D. On November 30, 2016, the PTAB issued decisions on the institution of inter partes reviews of U.S. Patent No. 6,667,061 (the ’061 patent), which relates to formulations for injectable suspensions having increased...
by Jones Day's PTAB Team | Dec 21, 2016 | Pharmaceutical, Trial Institution
By Jeff Giering, Ph.D. and Cary Miller, Ph.D. On November 30, 2016, the PTAB issued decisions on the institution of inter partes reviews of U.S. Patent No. 6,667,061 (the ’061 patent), which relates to formulations for injectable suspensions having increased...
by Jones Day's PTAB Team | Dec 20, 2016 | Pharmaceutical, Request for Reconsideration
By Lisamarie LoGiudice, Ph.D. and Cary Miller, Ph.D. In Mylan Pharmaceuticals Inc. and Amneal Pharmaceuticals LLC v. Yeda Research & Development Co. Ltd., IPR2015-00643; -00644; -00830, the PTAB granted-in-part Patent Owner Teva’s request for rehearing of the...
by Jones Day's PTAB Team | Dec 19, 2016 | Pharmaceutical, Trial Institution
By Wanli Tang, Ph.D. and J. Patrick Elsevier, Ph.D. On December 8, 2016, the PTAB issued six institution decisions in cases IPR2016-01127, IPR2016-01128, IPR2016-01129, IPR2016-01130, IPR2016-01131, and IPR2016-01132, agreeing to review claims of U.S. Patent Nos....
